Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Depreciation & Amortization (CF): 2020-2023

Historic Depreciation & Amortization (CF) for Candel Therapeutics (CADL) over the last 3 years, with Dec 2023 value amounting to $289,000.

  • Candel Therapeutics' Depreciation & Amortization (CF) rose 62.36% to $289,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $955,000, marking a year-over-year increase of 30.82%. This contributed to the annual value of $1.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q4 2023, Candel Therapeutics' Depreciation & Amortization (CF) stood at $289,000, which was up 44.50% from $200,000 recorded in Q3 2023.
  • In the past 5 years, Candel Therapeutics' Depreciation & Amortization (CF) registered a high of $289,000 during Q4 2023, and its lowest value of $6,000 during Q4 2020.
  • For the 3-year period, Candel Therapeutics' Depreciation & Amortization (CF) averaged around $159,750, with its median value being $182,500 (2021).
  • Within the past 5 years, the most significant YoY rise in Candel Therapeutics' Depreciation & Amortization (CF) was 2,866.67% (2021), while the steepest drop was 53.33% (2021).
  • Candel Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $6,000 in 2020, then soared by 2,866.67% to $178,000 in 2021, then remained steady at $178,000 in 2022, then skyrocketed by 62.36% to $289,000 in 2023.
  • Its last three reported values are $289,000 in Q4 2023, $200,000 for Q3 2023, and $236,000 during Q2 2023.